Table 3.

Incidence of cGvHD in period 1993-1996

Risk factorcGvHD, row %
NoLimitedExtensive
All patients 52 25 23 
Sex3-150,3-151    
 Male 48 25 27 
 Female 58 24 18  
Age, y3-150,3-151    
 Younger than 20 68 21 11  
 20-40 51 25 24  
 Older than 40 50 25 25  
Donor-recipient sex combination3-150,3-151    
 Donor (F) + recipient (M) 41 26 33  
 Other 56 24 20  
Interval between diagnosis and transplantation    
 Shorter than 12 mo 52 23 25  
 12 mo or longer 52 26 22  
aGvHD prevention3-150,3-151    
 T-cell depletion 51 28 21 
 Cyclo alone 52 20 28  
 Cyclo + mtx 55 25 20 
 Other 28 22 50  
Source of stem cells3-150,3-151    
 BM 54 25 21 
 PB 36 24 40  
aGvHD3-150,3-151    
 Grade 0 69 15 16  
 Grade I 46 36 18  
 Grade II 34 31 35  
 Grade III 40 18 42 
 Grade IV 75 5 20 
Risk factorcGvHD, row %
NoLimitedExtensive
All patients 52 25 23 
Sex3-150,3-151    
 Male 48 25 27 
 Female 58 24 18  
Age, y3-150,3-151    
 Younger than 20 68 21 11  
 20-40 51 25 24  
 Older than 40 50 25 25  
Donor-recipient sex combination3-150,3-151    
 Donor (F) + recipient (M) 41 26 33  
 Other 56 24 20  
Interval between diagnosis and transplantation    
 Shorter than 12 mo 52 23 25  
 12 mo or longer 52 26 22  
aGvHD prevention3-150,3-151    
 T-cell depletion 51 28 21 
 Cyclo alone 52 20 28  
 Cyclo + mtx 55 25 20 
 Other 28 22 50  
Source of stem cells3-150,3-151    
 BM 54 25 21 
 PB 36 24 40  
aGvHD3-150,3-151    
 Grade 0 69 15 16  
 Grade I 46 36 18  
 Grade II 34 31 35  
 Grade III 40 18 42 
 Grade IV 75 5 20 

Abbreviations are explained in Table 1.

F3-150

Indicates that the χ2 test for the comparison of the incidence of cGvHD (yes versus no) has a P < .05.

F3-151

Indicates that the χ2 test for a linear trend over the grades from no to extensive (severity) comparing the risk factor levels is significant at the .05 level.

View Large